服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
背景介绍 Tyrosine-protein kinase transmembrane receptor (ROR1) is an enzyme that in humans is encoded by the ROR1 gene. The ROR1 is expressed by tumor cells of various hematologic and solid malignancies and is largely absent from postnatal healthy cells and tissues. Treatment with a humanized monoclonal antibody specific for ROR1 (UC-961) can inhibit the capacity of ovarian cancer cells to migrate or engraft immune-deficient mice. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human ROR1 protein (Genbank NM_005012.3). Surface expression of ROR1 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of ROR1 expression (High, Medium, Low) to mimic different stages of cancer target cells with various ROR1 expression levels.
询价背景介绍 The surface antigen SLAMF7 is expressed on a fraction of normal lymphocytes, including subsets of natural killer (NK) cells, T cells, and B cells. It is a robust marker of normal plasma cells and malignant plasma cells in multiple myeloma. In contrast to CD138 (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from patient samples. SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma. It has been demonstrated that SLAMF7-CAR T cells prepared from patients and healthy donors confer potent antimyeloma reactivity. SLAMF7-CAR T cells confer fratricide of SLAMF7+/high normal lymphocytes. SLAMF7-CAR T cells represent a novel therapeutic agent for the treatment of patients with SLAMF7-expressing multiple myeloma malignancies. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human SLAMF7 protein, also known as CS1 or CD319 (Genbank #NM_021181). Surface expression of SLAMF7 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of SLAMF7 expression (High, Medium, Low) to mimic different stages of cancer target cells with various SLAMF7 expression levels.
询价背景介绍 The surface antigen SLAMF7 is expressed on a fraction of normal lymphocytes, including subsets of natural killer (NK) cells, T cells, and B cells. It is a robust marker of normal plasma cells and malignant plasma cells in multiple myeloma. In contrast to CD138 (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from patient samples. SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma. It has been demonstrated that SLAMF7-CAR T cells prepared from patients and healthy donors confer potent antimyeloma reactivity. SLAMF7-CAR T cells confer fratricide of SLAMF7+/high normal lymphocytes. SLAMF7-CAR T cells represent a novel therapeutic agent for the treatment of patients with SLAMF7-expressing multiple myeloma malignancies. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human SLAMF7 protein, also known as CS1 or CD319 (Genbank #NM_021181). Surface expression of SLAMF7 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of SLAMF7 expression (High, Medium, Low) to mimic different stages of cancer target cells with various SLAMF7 expression levels.
询价背景介绍 The surface antigen SLAMF7 is expressed on a fraction of normal lymphocytes, including subsets of natural killer (NK) cells, T cells, and B cells. It is a robust marker of normal plasma cells and malignant plasma cells in multiple myeloma. In contrast to CD138 (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from patient samples. SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma. It has been demonstrated that SLAMF7-CAR T cells prepared from patients and healthy donors confer potent antimyeloma reactivity. SLAMF7-CAR T cells confer fratricide of SLAMF7+/high normal lymphocytes. SLAMF7-CAR T cells represent a novel therapeutic agent for the treatment of patients with SLAMF7-expressing multiple myeloma malignancies. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human SLAMF7 protein, also known as CS1 or CD319 (Genbank #NM_021181). Surface expression of SLAMF7 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of SLAMF7 expression (High, Medium, Low) to mimic different stages of cancer target cells with various SLAMF7 expression levels.
询价背景介绍 CD37 expression is restricted to cells of the immune system, with highest abundance on mature B cells, and lower expression is found on T cells and myeloid cells. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. It is also expressed in B-cell non-Hodgkin Lymphomas, in chronic lymphocytic leukemia (CLL), and in some cases of cutaneous and peripheral T-cell lymphomas. CAR-37 T cells have demonstrated antigen-specific activation, cytokine production, and cytotoxic activity in models of B- and T-cell lymphomas in vitro and in vivo, including patient-derived xenografts. T cells expressing anti-CD37 CAR have substantial activity against 2 different lymphoid lineages, without evidence of significant T cell fratricide. Furthermore, anti-CD37 CARs have been combined with anti-CD19 CARs to generate dual-specific CAR T cells capable of recognizing CD19 and CD37 alone or in combination. CD37-CAR T cells represent a novel therapeutic agent for the treatment of patients with CD37-expressing lymphoid malignancies. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human CD37 protein, also known as GP52-40; TSPAN26; leukocyte antigen CD37 (Genbank #NM_001774). Surface expression of CD37 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD37 expression, (High, Medium, Low), to mimic different stages of cancer target cells with various CD37 expression levels.
询价背景介绍 CD37 expression is restricted to cells of the immune system, with highest abundance on mature B cells, and lower expression is found on T cells and myeloid cells. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. It is also expressed in B-cell non-Hodgkin Lymphomas, in chronic lymphocytic leukemia (CLL), and in some cases of cutaneous and peripheral T-cell lymphomas. CAR-37 T cells have demonstrated antigen-specific activation, cytokine production, and cytotoxic activity in models of B- and T-cell lymphomas in vitro and in vivo, including patient-derived xenografts. T cells expressing anti-CD37 CAR have substantial activity against 2 different lymphoid lineages, without evidence of significant T cell fratricide. Furthermore, anti-CD37 CARs have been combined with anti-CD19 CARs to generate dual-specific CAR T cells capable of recognizing CD19 and CD37 alone or in combination. CD37-CAR T cells represent a novel therapeutic agent for the treatment of patients with CD37-expressing lymphoid malignancies. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human CD37 protein, also known as GP52-40; TSPAN26; leukocyte antigen CD37 (Genbank #NM_001774). Surface expression of CD37 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD37 expression, (High, Medium, Low), to mimic different stages of cancer target cells with various CD37 expression levels.
询价背景介绍 B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells, except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human CD19 protein, also known as B4 or CVID3, (Genbank #NM_001770). Surface expression of CD19 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD19 expression (High, Medium, Low) to mimic different stages of cancer target cells with various CD19 expression levels.
询价背景介绍 B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells, except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human CD19 protein, also known as B4 or CVID3, (Genbank #NM_001770). Surface expression of CD19 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD19 expression (High, Medium, Low) to mimic different stages of cancer target cells with various CD19 expression levels.
询价背景介绍 B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells, except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human CD19 protein, also known as B4 or CVID3, (Genbank #NM_001770). Surface expression of CD19 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD19 expression (High, Medium, Low) to mimic different stages of cancer target cells with various CD19 expression levels.
询价
